StockData
Vericel Corp logo

Vericel Corp (VCEL) stock

VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/30254% above fair value
$57.42−2.03 (-3.41%)

Close on Nov 12, 2026Market cap $2.94BP/E 97.3Yield –

Earnings

Vericel's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$85.40M
+26.5% on a year earlier
EPS, Q3 FY2026
$0.27
$0.10 a year earlier
Latest guidance
Raised
Nov 5, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of Vericel's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open$85.40M+26.5%$0.27Release
Q2 FY2026ended Jun 30, 2026Jul 30, 2026before the open$77.50M+22.6%$0.04Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open$68.40M+30.0%-$0.12Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$92.90M+23.2%$0.45Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open$67.50M+16.6%$0.10Release
Q2 FY2025ended Jun 30, 2025Jul 31, 2025before the open$63.20M+19.9%-$0.01Release
Q1 FY2025ended Mar 31, 2025May 8, 2025before the open$52.60M+2.5%-$0.23Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open$75.40M+16.0%$0.38Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open$57.90M+27.0%-$0.02Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024before the open$52.70M+14.8%-$0.10Release
Q1 FY2024ended Mar 31, 2024May 8, 2024before the open$51.30M+25.1%-$0.08Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Vericel's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total revenueGAAPFY2026$344.00M – $346.00M–NewNov 5, 2026
Total revenueFY2026$330.00M – $340.00M$326.00M – $336.00MRaisedJul 30, 2026
Total revenueFY2026$316.00M – $326.00M–NewFeb 26, 2026
gross marginGAAPFY202675%–NewNov 5, 2026
gross marginFY202675%75%ReaffirmedJul 30, 2026
Gross marginFY202675%–NewFeb 26, 2026
adjusted EBITDA marginnon-GAAPFY202628%27%RaisedNov 5, 2026
adjusted EBITDA marginnon-GAAPFY202627%–NewJul 30, 2026
adjusted EBITDA marginnon-GAAPFY202627%–NewMay 7, 2026
Burn Care revenueFY2026$46.00M – $50.00M–LoweredJul 30, 2026
MACI revenueFY2026$284.00M – $290.00M–NewJul 30, 2026
MACI revenueFY2026$280.00M – $286.00M–NewFeb 26, 2026

Guidance vs results

The last range Vericel gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$237.50M – $239.50M$276.20MΣ4QAbove range
Q2 FY2025Revenue growth+22% – +25%+19.92%Below range

Guidance history

Every forecast Vericel put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026adjusted EBITDA marginFY202628%Raised
Nov 5, 2026gross marginFY202675%New
Nov 5, 2026total revenueFY2026$344.00M – $346.00MNew
Nov 5, 2026MACI revenueFY2026$290.00M – $292.00MLowered
Nov 5, 2026Burn Care revenueFY2026$54.00MLowered
Jul 30, 2026adjusted EBITDA marginFY202627%New
Jul 30, 2026gross marginFY202675%Reaffirmed
Jul 30, 2026Burn Care revenueFY2026$46.00M – $50.00MLowered
Jul 30, 2026MACI revenueFY2026$284.00M – $290.00MNew
Jul 30, 2026Total revenueFY2026$330.00M – $340.00MRaised
May 7, 2026gross marginFY202675%New
May 7, 2026adjusted EBITDA marginFY202627%New
May 7, 2026Total revenueFY2026$326.00M – $336.00MNew
May 7, 2026Burn Care revenueFY2026$44.00M – $48.00MLowered
May 7, 2026MACI revenueFY2026$282.00M – $288.00MLowered
Feb 26, 2026Adjusted EBITDA marginFY202627%New
Feb 26, 2026Gross marginFY202675%New
Feb 26, 2026MACI revenueFY2026$280.00M – $286.00MNew
Feb 26, 2026Total revenueFY2026$316.00M – $326.00MNew
Nov 6, 2025gross marginFY202574%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Vericel filed with the SEC as exhibits to Form 8-K or 6-K

  1. Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
    Results
  2. Quarterly results release
    Results
  3. Quarterly results release
    Results
  4. Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results
    Results
  5. Vericel Announces Preliminary 2025 Financial Results and Business Updates
    Results
  6. Vericel Reports Third Quarter 2025 Financial Results
    Results
  7. Vericel Reports Second Quarter 2025 Financial Results
    Results
  8. Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
    Results
  9. Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
    Results
  10. Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets
    Results
  11. Advanced Therapies for the Sports Medicine & Severe Burn Care Markets 43Rd Annual
    Results
  12. Vericel Reports Third Quarter 2024 Financial Results
    Results
  13. Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
    News
  14. Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
    News
  15. Vericel Reports Second Quarter 2024 Financial Results
    Results

See a number that looks wrong?